US completes first USD 500 mln sale of Venezuela oil: Report says

According to the Semafor report, revenue from the oil sales is currently being held in bank accounts controlled by...

Semaglutide patent expiry opens over Rs 50,000 Crore opportunity

In India, the launch of generic semaglutide, expected in the first quarter of FY27, is projected to boost overall...

AOL-SSIAST Rewa Model Farm Project Strengthens Natural Farming

Bengaluru (Karnataka) [India], December 30: The Rewa Model Farm Project marked a significant milestone for the...

Manupatra Unveils AI Search, Once Again Redefining the Future

New Delhi [India], December 19: Twenty-five years ago, Manupatra disrupted the way legal research was conducted in...

India and Obesity: SMSRC Insights Report reveals

New Delhi [India], December 3: India stands at an inflexion point in its battle with obesity. For many years,...

Novo Nordisk India partners with Emcure Pharma to launch Poviztra

The collaboration aims to enhance the distribution and marketing of semaglutide for weight loss, particularly...

CDSCO approves injection for Type 2 diabetes patients

In a statement provided to ANI, Novo Nordisk has stated that Ozempic is intended for individuals with Type 2...

Paralympic medallist Hokato Sema aims to surpass 15m mark 

"I know breaking records is not just about power--it's about precision, patience, and pushing myself beyond limits....

“The Rising Dawn” by Semal A. More — A Stirring Tale of Injustice

New Delhi [India], August 8: Evincepub Publishing proudly announces the release of The Rising Dawn, a powerful new...

Semantic Layer Takes Center Stage at ICDSA 2025 Hosted by MNIT

Jaipur (Rajasthan) [India], July 31: The 6th International Conference on Data Science and Applications (ICDSA 2025),...

Sumit, Navdeep bag gold in Indian Open Para Athletics C'ship

Shree Kanteerava Stadium in Bengaluru roared with pride and purpose as Day 1 of the 7th Indian Open Para Athletics...

Tirzepatide tops semaglutide in trial

Eli Lilly and Company announced on Monday detailed results from SURMOUNT-5, a phase 3b open-label clinical trial,...